MetaCap

ImageneBio (IMA) vs MiNK Therapeutics (INKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MiNK Therapeutics (INKT) has outperformed ImageneBio (IMA) over the past year, losing 24.1% versus a loss of 44.9%. Over five years, INKT leads with a -96.0% price change compared with -97.9% for IMA. ImageneBio is the larger company by market cap ($48.8 million vs $41.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMA-44.87%INKT-24.05%
+39%-10%-59%
Nov 21, 20251 yearNov 20, 2026
IMA-97.89%INKT-94.98%
+31%-36%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMA versus INKT key metrics
MetricIMAINKT
Share price$3.92$8.02
Market cap$48.83M$41.17M
1-day change0.00%-6.85%
YTD return-43.19%-28.07%
1-year return-44.87%-24.05%
5-year return-97.86%-95.99%
EPS (TTM)$-2.11$-2.23
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$800.00K—
Revenue growth (YoY)-77.14%—
Net income (latest FY)$-45.35M$-12.49M
Operating margin-6056.38%—
Net margin-5668.63%—
52-week high$7.60$16.93
52-week low$3.00$7.76
Distance from 52-week high-48.42%-52.62%
Analyst consensusnonestrong_buy
Avg. price target upside+359.18%+386.28%
Average volume15.86K15.74K
Shares outstanding12.46M5.13M
Employees1815
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INKT has outperformed IMA by 20.8 percentage points over the past year.

About ImageneBio

IMA stock →

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About MiNK Therapeutics

INKT stock →

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees

IMA vs INKT FAQ

Which is bigger, ImageneBio or MiNK Therapeutics?

ImageneBio (IMA) is larger, with a market capitalization of $48.83M compared with $41.17M for MiNK Therapeutics (INKT).

Which stock has performed better over the past year, IMA or INKT?

INKT returned -24.05% over the past 12 months, compared with -44.87% for IMA (price return, excluding dividends). Past performance does not predict future results.

Are ImageneBio and MiNK Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons